ClinicalTrials.gg
Enrolling by invitationNCT07583342Updated May 13, 2026

Evaluating RELiZORB Use for the Treatment of Feeding Intolerance in Adults With Moderate to Severe Acute Pancreatitis

A Phase 4 interventional study of RELiZORB digestive enzyme (immobilized lipase) cartridge in Acute Pancreatitis (AP) and Enhancing Enteral Nutrition Tolerance, sponsored by Northwell Health. Enrolling by invitation at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Northwell Health · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Dec 2025, registered Mar 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 139 studies in Pancreatitis with a site in United States — 44 open to participants now, 49 under way, 2 of them phase 3. Pancreatitis · United States.

Planned enrollment
82nd of 97
15 · median 60
Started
2025
with 8 others
Phase 4
11 of 139
5 open now
Primary completion
2026-12
later than 11 of 48 live
Registered
135th of 139
by date

Among the 139 studies in Pancreatitis with a site in United States, this one is the 82nd largest by planned enrollment of the 97 interventional ones that give a count, is one of 9 that started in 2025, is one of 11 in phase 4, reaches primary completion later than 11 of the 48 other live ones, and was the 135th registered.

Pancreatitis

558 studies on the registry are indexed under Pancreatitis; 165 are open to participants now.

Browse Pancreatitis studies →

Open to participants now

44 of the 139 studies in Pancreatitis with a site in United States are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 112 Pancreatitis studies recruiting now, 62 (55%) set no upper age limit and 27 (24%) stop at 75 or younger; 14 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Pancreatitis with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to learn if Relizorb, a fat-digesting enzyme, can improve tolerance of tube feeds in adult patients with moderate to severe pancreatitis. The main question it aims to answer is:

Does Relizorb allow more nutrition to be delivered to participants than they received without it?

Participants will be observed with standard, universal monitoring after adding Relizorb to their nutrition regimen.

03

Conditions studied

  • Acute Pancreatitis (AP)
  • Enhancing Enteral Nutrition Tolerance

Browse trials for

Keywords

  • RELiZORB
  • Acute Pancreatitis
  • AP
  • EN support
  • Enteral nutrition (EN)
  • Immobilized lipase cartridge
  • Digestive enzyme cartridge
  • Feeding intolerance
  • Enteral nutrition intolerance
  • Fat malabsorption
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 18 + years of age
  • Admission to the Surgical Intensive Care Unit in the Northwell Health hospital system
  • Moderate to severe acute pancreatitis based on Atlanta criteria
  • Inability to tolerate ≥75% of goal EN (25 kcal/kg/d)

Exclusion criteria

Exclusion Criteria:

  • Moribund patients expected to expire within 120 hours
  • Evidence of unresolved intestinal obstruction, ischemia, bleeding, perforation, fistulas or tract discontinuity, or other for enteral nutrition
  • Diagnosis or evidence of C. Difficile or other gastrointestinal infection that may manifest with diarrhea
  • Pre-existing constipation defined as laxative or stool softener use prior to admission to the hospital
  • Patients receiving cancer-related treatment in the last 3 months
  • History of cystic fibrosis
  • Any other reason that the treating or investigator team considers to be a contraindication to enteral nutrition
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Relizorb treatment

    Patients with moderate to severe pancreatitis who are not tolerating sufficient enteral nutrition will have a lipase-containing cartridge (Relizorb) placed in-line with their enteral nutrition tubing, to digest the fat in the formula prior to entering the patient's intestine.

    Device: RELiZORB digestive enzyme (immobilized lipase) cartridge

Interventions

  • DeviceRELiZORB digestive enzyme (immobilized lipase) cartridge

    An in-line digestive enzyme cartridge designed for hydrolyzing lipids within enteral nutrition will be used to improve tube feed tolerance in patients with moderate to severe pancreatitis.

06

What researchers measure

Primary outcomes

  1. Percent of goal nutrition delivered at 72 hours

    Change from baseline in percentage of goal enteral nutrition (kcal/kg/day) received 3 days (72 hours) following initiation of RELiZORB. Baseline is considered the 24 hours prior to RELiZORB start.

    Time frame: From enrollment to the end of treatment at 72 hours

Secondary outcomes

  1. Percent of goal nutrition delivered at 24 hours

    Change from baseline in goal percentage of enteral nutrition (kcal/kg/day) received 1 day (24 hours) following initiation of RELiZORB.

    Time frame: From enrollment to 24 hours after starting RELiZORB

  2. Responders at 72 hours

    Percent of patients considered responders defined as receiving ≥80% of their daily enteral nutritional goal 3 days (72 hours) following initiation of RELiZORB use.

    Time frame: From enrollment to end of treatment at 72 hours

  3. Responders at 24 hours

    Percent of patients considered responders defined as receiving ≥80% of their daily enteral nutritional goal 1 day (24 hours) following initiation of RELiZORB use.

    Time frame: From enrollment to 24 hours after starting treatment

  4. Vomiting

    Change in the number of vomiting episodes per 24 hour period from baseline to 24 and 72 hours following initiation of RELiZORB use

    Time frame: From enrollment to completion of treatment at 72 hours

  5. Stool volume

    Change in stool volume per 24 hour period from baseline to 24 and 72 hours following initiation of RELiZORB use (if rectal tube is in place)

    Time frame: From enrollment to completion of treatment at 72 hours

  6. Bowel movements

    Change in number of bowel movement episodes in 24 hours from baseline to 24 hours and 72 hours after RELiZORB (if no rectal tube)

    Time frame: From enrollment to completion of treatment at 72 hours

  7. Feeding Interruptions

    Number of unplanned interruptions in tube feeding from baseline to 24 hours and 72 hours following initiation of RELiZORB use

    Time frame: From enrollment to completion of treatment at 72 hours

07

Study locations

5 sites
08

References and documents

Individual participant data

Plan to share: No — Considering the small sample size, there is a concern for breach of confidentiality if IPD were shared.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2026
First posted
May 13, 2026
StartActual
Dec 8, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07583342
Lead sponsor
Northwell Health
Collaborators
Alcresta Therapeutics, Inc.
Responsible party
Laura Hansen (Director of Surgical ICU, Surgery, Acute Care in Lenox Hill Hospital, Northwell Health) — Principal investigator
First posted
May 13, 2026
Start date
Dec 8, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
May 13, 2026

Study contacts

Laura Hansen, MD
principal investigator · Northwell Health
Rafael Barrera, MD
principal investigator · Northwell Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion